Tag Archives: Ulcerative colitis

Takeda Reports VERDICT Trial Evidence of Reduced Ulcerative Colitis Complications with ENTYVIO Disease Clearance Target

Exterior view of a Takeda research and office complex with the Boston skyline in the background.

Phase 4 findings showed a hazard ratio of 0.33 for a first UC-related complication versus symptomatic remission alone, with results presented at UEG Week 2026. IN BRIEFKEY TAKEAWAYSFAQs Takeda has announced new results from the Phase 4 VERDICT trial of … Read the full press release →

Sandoz and Samsung Bioepis Expand Strategic Partnership to Advance Global Biosimilar Pipeline and Market Reach

(IN BRIEF) Sandoz has announced a new partnership with Samsung Bioepis to develop and commercialize up to five biosimilar medicines, beginning with a vedolizumab biosimilar targeting inflammatory bowel diseases. The agreement grants Sandoz global commercialization rights in most markets, while … Read the full press release →

Global Study Links Gut Oxygen Levels and Oral Bacteria to the Earliest Stages of IBD

(IN BRIEF) An international research team has identified striking changes in gut bacteria that occur at the very beginning of inflammatory bowel disease, based on a unified analysis of microbiome data from more than 1,700 untreated patients across 11 countries. … Read the full press release →

University of Exeter and Royal Devon NHS Launch Study to Cut Delays in Diagnosing Crohn’s and Colitis

(IN BRIEF) The Royal Devon University Healthcare NHS Foundation Trust and the University of Exeter have launched the RAPID-IBD study to speed up diagnosis of Crohn’s disease and ulcerative colitis, conditions that affect 1 in 100 people in the UK. … Read the full press release →

Fresenius Kabi Secures Global Rights to PB016 Vedolizumab Biosimilar from Polpharma Biologics

(IN BRIEF) Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the Middle East and North Africa—once approved. Vedolizumab treats Crohn’s disease and ulcerative colitis, and PB016 references Takeda’s Entyvio®. The transaction … Read the full press release →

Sanofi and Teva Collaborate on Inflammatory Bowel Disease Treatment, TEV’574, in $1.5 Billion Deal

(IN BRIEF) Sanofi and Teva Pharmaceuticals have announced a collaboration to co-develop and co-commercialize TEV’574, a promising asset currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, both forms of inflammatory bowel disease (IBD). … Read the full press release →

Milestone for the diagnosis of inflammatory bowel disease

Clinicians at the University Hospital Erlangen show how a new laser-based imaging technique termed MSOT can detect inflammation more accurately than current non-invasive diagnostic procedures and thereby help reduce the burden to patients MUNICH, 30-Mar-2017 — /EuropaWire/ — Ulcerative colitis … Read the full press release →